iRadimed IRMD Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $23.61M+19.3% | $22.48M+16.9% | $21.18M+13.7% | $20.66M+10.8% | $19.78M+10.4% | ||
| $1.43M+81.6% | $1.17M+42.5% | $980.53K+18.4% | $794.38K-3.2% | $785.91K-2.8% | ||
| $2.78M+2.0% | $2.92M+15.6% | $2.88M+19.0% | $2.84M+22.4% | $2.72M+19.3% | ||
| -$2.46M— | -$2.73M— | -$291.82K— | —— | —— | ||
| -$29K+59.6% | -$84K+11.6% | -$86.73K-336% | -$146.42K— | -$71.79K— | ||
| —— | —— | —— | —— | —— | ||
| $1.84M+163% | $1.43M+146% | -$416.88K-802% | -$1.68M-163% | -$2.91M-147% | ||
| -$408K— | -$76K— | $48.89K— | —— | —— | ||
| —— | —— | —— | —— | $122.88K— | ||
| $617K+2,264% | $132K-58.8% | $148.26K-46.6% | $906.3K+104% | -$28.52K-109% | ||
| —— | —— | —— | —— | -$225K— | ||
| $1.35M— | $1.6M— | $1.43M— | $1.24M— | —— | ||
| —— | —— | —— | —— | -$5.54K— | ||
| $28.95M+11.2% | $24.95M-2.6% | $25.01M+6.2% | $27.14M+71.5% | $26.03M+105% | ||
| $4.47M-60.9% | $7.77M-3.0% | $10.26M+78.6% | $12.93M+476% | $11.43M+769% | ||
| —— | —— | —— | —— | —— | ||
| -$4.97M+59.4% | -$8.42M+4.5% | -$11.06M-73.0% | -$13.81M-390% | -$12.26M-535% | ||
| $15.43M+96.3% | $15.04M+10.0% | $8.39M— | $8.12M— | $7.86M— | ||
| $2.5M+237% | $2.56M+272% | $784.2K+35.8% | $772.47K+30.7% | $740.12K+18.5% | ||
| -$17.93M-109% | -$17.6M-22.8% | -$9.15M+24.9% | -$8.87M+13.8% | -$8.57M-1.8% | ||
| $6.04M+16.1% | -$1.08M-143% | $4.81M— | $4.46M— | $5.2M— | ||
| $3.93M-38.0% | $3.92M-39.8% | $4.55M-19.7% | $5.85M+4.4% | $6.33M— | ||
| -$2.46M— | -$2.73M— | -$291.82K— | —— | —— | ||
| —— | —— | —— | —— | $122.88K— | ||
| —— | —— | —— | —— | -$225K— | ||
| $21.41K— | $41.41K— | $31.11K— | —— | —— | ||
| $617K+2,264% | $132K-58.8% | $148.26K-46.6% | $906.3K+104% | -$28.52K-109% | ||
| $2.59M+339% | $2.58M+228% | $1.36M— | $186.4K— | $589.5K— | ||
| —— | —— | —— | —— | —— | ||
| $100K— | $47K— | —— | —— | —— | ||
| -$29K+59.6% | -$84K+11.6% | -$86.73K-336% | -$146.42K— | -$71.79K— | ||
| —— | —— | —— | —— | —— | ||
| $1.35M— | $1.6M— | $1.43M— | $1.24M— | —— | ||
| $3.93M-38.0% | $3.92M-39.8% | $4.55M-19.7% | $5.85M+4.4% | $6.33M— | ||
| $24.47M+67.6% | $17.18M-2.5% | $14.75M-17.1% | $14.21M+4.6% | $14.6M+28.2% | ||
| $24.47M+67.6% | $17.18M-2.5% | $14.75M-17.1% | $14.21M+4.6% | $14.6M+28.2% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does iRadimed generate?
- iRadimed (IRMD) generated $28.9M in operating cash flow over the trailing twelve months.
- What is iRadimed's free cash flow?
- After $4.5M of capital expenditures, iRadimed's free cash flow was $24.5M over the trailing twelve months, up 67.6% year over year.
- Where does iRadimed's cash flow data come from?
- Every line is extracted from iRadimed's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
